Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Board Meeting Intimation
Board of Cipla Ltd will meet on 13 May 2026 to consider and approve standalone and consolidated audited financial results for the quarter and year ended 31 Mar 2026, and may recommend a final dividend; trading window closed Apr 1–May 15, 2026.
Change in Directors/KMP
Cipla has categorised Mr Saurabh Gambhir and Mr Satyavan Manikani as Senior Management Personnel effective 1 Apr 2026; Mr Umang Vohra resigned as Director w.e.f. 1 Apr 2026 on completion of term.
Change in Management
Cipla's board (30 Mar 2026) designated Mr Saurabh Gambhir (Head – Strategy & M&A) and Mr Satyavan Manikani (Chief Portfolio Head, Global) as Senior Management Personnel effective 1 Apr 2026 after Mr Achin Gupta took charge as MD & Global CEO; Mr Umang Vohra resigned as director effective 1 Apr 2026.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Cipla Ltd (CIPLA) is currently trading at 1,193.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.55 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cipla Ltd has a market capitalization of approximately 96,400.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 96,400.78 Cr, Cipla Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cipla Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cipla Ltd is 21.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Achin Gupta, the current Global Chief Operating Officer, is proposed to be the new Managing Director and Global CEO, effective April 1, 2026, subject to shareholder approval.
Achin Gupta, the current Global Chief Operating Officer, is proposed to be the new Managing Director and Global CEO of Cipla, subject to shareholder approval.
The 'Biopharma Shakti' scheme is the most significant announcement. With a INR 10,000 crore outlay, it aims to make India a global biopharma hub, directly supporting Cipla's focus on biologics, biosimilars, and R&D.
The profit decline was primarily due to a one-time charge of ₹276 crore for new labour laws, lower sales from its gRevlimid product in the US market, and overall pressure on operating margins.
Bearish
3
Neutral
4
Bullish
7
Bearish
35
Neutral
4
Bullish
7
Bearish
32
Neutral
0
Bullish
0
Discovery themes featuring this stock
Upcoming Result Date: May 12, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability.
Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products.
Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Pharmaceuticals & Biotechnology
Pharmaceuticals
96,401 Cr
Low Risk
21.2
30.9
2.1
2.9
1,672.20
1,165.55
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2276.80 | 1,04,091 Cr | 20.96 | 5.30 | 0.53 | 22.03 | 21.92 | 13.94 | ||
1218.00 | 1,01,628 Cr | 18.23 | 2.82 | 0.66 | 16.03 | 18.66 | 10.16 | ||
1193.40 | 96,401 Cr | 21.21 | 2.93 | 1.34 | 16.53 | 21.05 | 11.32 | ||
864.25 | 86,964 Cr | 17.61 | 3.44 | 1.27 | 19.44 | 19.08 | 10.52 | ||
1990.00 | 82,460 Cr | 46.23 | 5.39 | 0.00 | 11.45 | 12.34 | 6.26 | ||
1335.95 | 77,592 Cr | 22.25 | 2.21 | 0.00 | 9.77 | 12.69 | 6.63 | ||
5271.35 | 62,857 Cr | 26.58 | 4.71 | 0.86 | 17.69 | 18.13 | 11.95 | ||
| Median: 7 Co. | — | 1335.95 | 86,964 Cr | 21.21 | 3.44 | 0.66 | 16.53 | 18.66 | 10.52 |
